NCT05780307View on ClinicalTrials.gov

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

March 10, 2024

Study Completion Date

October 26, 2025

Conditions
Advanced Solid TumorNon-small Cell Lung CancerSmall Cell Lung CancerBreast CancerSquamous Cell Cancer of Head and NeckColorectal Cancer
Interventions
DRUG

IMM2520

IMM2520 will be administered once a week intravenously at Day 1, Day8, Day 15 and Day 22 each cycle for up to 48 weeks.

Trial Locations (1)

250117

RECRUITING

Affilated Cancer Hospital of Shandong First Medical University, Jinan

All Listed Sponsors
collaborator

Shandong Cancer Hospital and Institute

OTHER

lead

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

OTHER